抗药性机制和特斯图祖马布的前景
Lizhe Wang1, Yu Wang1, Yueyang Li1
1The Third Affiliated Hospital of Anhui Medical University, Hefei first people's Hospital, Hefei, China.
Frontiers in oncology
|December 10, 2024
概括
在HER2阳性乳腺癌患者中,超过一半的患者对trastuzumab治疗没有反应. 本综述探讨了耐药性机制,包括遗传,分子和微环境因素,以指导新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫治疗是一种免疫疗法.
背景情况:
- HER2阳性乳腺癌占所有乳腺癌病例的15-20%.
- 特拉斯图祖马布是HER2阳性晚期乳腺癌的标准第一线治疗方法.
- 超过50%的患者表现出对trastuzumab的原发性或获得性耐药性.
研究的目的:
- 审查目前对HER2阳性乳腺癌中trastuzumab耐药机制的研究.
- 从遗传,分子,信号通路和瘤微环境的角度阐明抵抗机制.
- 概述新兴的研究和新的治疗策略,以克服特鲁祖马布耐药性.
主要方法:
- 对现有研究的文献综述 关于逆苏祖马布耐药性的研究.
- 针对HER2的抵抗机制的分析,包括遗传位置,分子结构,信号通路和瘤微环境.
- 综合当前的研究进展,并确定新的治疗途径.
主要成果:
- 抵抗机制是多方面的,涉及遗传变化,HER2通路的重新激活和瘤微环境调节.
- 了解这些机制对于预测治疗反应和开发替代疗法至关重要.
- 目前正在研究几种新的策略,以克服特拉斯图祖马布耐药性.
结论:
- 特拉斯图祖马布耐药性是HER2阳性乳腺癌管理中的重大临床挑战.
- 对抗药性机制的全面理解对于提高治疗疗效至关重要.
- 未来的研究应该专注于开发有针对性的疗法和组合策略,以克服耐药性并改善患者的治疗结果.
更多相关视频
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
1.9K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.5K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Tumor Immunotherapy
476
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
476
